History of Avanir
Founded with focus
Avanir started out as Lidak Pharmaceuticals, Inc. in 1988, developing research-based treatments to meet patient needs. Our first pharmaceutical product was Abreva®, an over-the-counter cold sore treatment that was out-licensed to another company.
Our quest to bring research-based treatments to patients led us to develop treatments for cardiovascular, autoimmune and infectious diseases. We also changed our name to Avanir Pharmaceuticals, Inc.
CNS at the Forefront
During this pivotal year, we began development of products containing dextromethorphan – a key ingredient in our CNS-focused approved product and many drugs under development.
In October, we received an FDA approval for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 mg dose strength.
NUEDEXTA® is launched in the United States
We entered into a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for disorders of the central nervous system.
In June, the European Commission approved NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 and 30/10 mg dose strength.
*product is currently not marketed in Europe
On July 2, we announced a development and commercialization agreement with OptiNose™ AS for a new investigational product for the acute treatment of migraine.
In 2015, Avanir became a subsidiary of Otsuka America, Inc., a holding company owned by Otsuka Pharmaceutical Co., Ltd. This move provided the support of a leading global pharmaceutical company while allowing our business to remain nimble and flexible.
ONZETRA® Xsail® approved
(sumatriptan nasal powder) 11 mg per nosepiece
We received FDA approval of ONZETRA® Xsail® in January and launched it in the United States market in May.